ALCAM and BCAM: Two New Breast Cancer Biomarkers

ALCAM 和 BCAM：两种新的乳腺癌生物标志物

• 批准号: 7798163
• 负责人: ELEFTHERIOS P DIAMANDIS
• 金额: $ 13.28万
• 依托单位: SINAI HEALTH SYSTEM
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7798163
• 关键词: Activated-Leukocyte Cell Adhesion Molecule; Affect; Aftercare; Applications Grants; B-Lymphocytes; Benign; Biological Assay; Biological Markers; Blinded; Blood; Breast; Breast Carcinoma; Categories; Cell Adhesion Molecules; Clinical; Data; Diagnosis; Diagnostic; Diagnostic Neoplasm Staging; Disease; Disease Progression; Early Diagnosis; Family; Goals; Health; Human; Immunoassay; In Situ; Laboratories; Lead; Measures; Methods; Modality; Monitor; Operative Surgical Procedures; Patient Monitoring; Patients; Play; Quality of life; Receiver Operating Characteristics; Recovery; Regimen; Reproducibility; Role; Sampling; Sensitivity and Specificity; Series; Serum; Staging; Statistical Data Interpretation; Symptoms; Therapeutic; Time; Woman; advanced disease; base; breast cancer diagnosis; chemotherapy; combat; effective therapy; improved; malignant breast neoplasm; novel; polyclonal antibody; public health relevance; response; validation studies

DESCRIPTION (provided by applicant): Breast cancer is a major health problem affecting millions of women worldwide. One of the ways to combat breast cancer is by early diagnosis and administration of effective therapy. For those patients whose disease is diagnosed at a late stage, accurate monitoring for assessing response to treatment is important. Unfortunately, until now, there is no effective means for diagnosing breast cancer or for monitoring, due to the lack of high-quality blood-based biomarkers. In this grant application, our aim is to validate two newly discovered candidate breast cancer biomarkers. We will use samples that have been collected before treatment [for the diagnostic application] and samples that have been collected during therapy, over many years [for the application of monitoring response to therapy]. Our preliminary data indicate that these newly discovered biomarkers perform better than the classical and commercially available breast cancer biomarker, CA15.3. If our results are promising, they may lead to new ways for early diagnosis of breast cancer and for better monitoring of those patients who are treated with chemotherapy or other regimens. Our positive data may improve the way breast cancer is diagnosed and monitored, with the ultimate goal of extending patient survival and improve quality of life. PUBLIC HEALTH RELEVANCE: We have recently discovered two new breast cancer biomarkers. Our preliminary data are highly promising, regarding use of these biomarkers for early diagnosis of breast cancer and for monitoring patients who have advanced disease and are treated with various modalities. If we are successful, these two new novel biomarkers may play a major role in improving the diagnosis of early breast cancer and in optimizing therapeutic regimens of patients who already have the disease.

描述(由申请者提供)：乳腺癌是影响全球数百万女性的主要健康问题。对抗乳腺癌的方法之一是早期诊断和实施有效的治疗。对于那些疾病被诊断为晚期的患者，准确的监测以评估治疗反应是重要的。不幸的是，到目前为止，由于缺乏高质量的血液生物标记物，还没有有效的手段来诊断乳腺癌或进行监测。在这项拨款申请中，我们的目标是验证两个新发现的候选乳腺癌生物标记物。我们将使用治疗前收集的样本[用于诊断应用]和治疗期间多年收集的样本[用于监测治疗反应]。我们的初步数据表明，这些新发现的生物标记物的表现优于经典的和商业上可用的乳腺癌生物标记物CA15.3。如果我们的结果是有希望的，它们可能会为乳腺癌的早期诊断和对接受化疗或其他方案治疗的患者进行更好的监测带来新的方法。我们的积极数据可能会改善乳腺癌的诊断和监测方式，最终目标是延长患者生存时间和提高生活质量。与公共健康相关：我们最近发现了两个新的乳腺癌生物标志物。我们的初步数据非常有希望，因为这些生物标记物用于乳腺癌的早期诊断和监测患有晚期疾病并接受各种治疗的患者。如果我们成功，这两个新的生物标志物可能会在改善早期乳腺癌的诊断和优化已患乳腺癌患者的治疗方案方面发挥重要作用。